Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.45 |
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.44 |
| ▸ | GHSR | Q92847 | 2/20 | 0.43 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.42 |
| ▸ | PDIA6 | Q15084 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4802402 | 0.81 | KCNH2 (0.47) | KCNH2HDAC1HDAC2ERN1HDAC3 | |
| SCHEMBL4804005 | 0.81 | GHSR (0.48) | KCNH2ERN1GHSRCA2CA9 | |
| SCHEMBL9335104 | 0.76 | KCNH2 (0.55) | KCNH2HDAC1HDAC2ERN1HDAC3 | |
| SCHEMBL172744 | 0.75 | ERN1 (0.58) | KCNH2HDAC1HDAC2ERN1HDAC3 | |
| SCHEMBL813100 | 0.75 | CA2 (0.52) | PDIA6CA2CA9CA1CA12 | |
| SCHEMBL13494207 | 0.75 | KCNH2 (0.70) | KCNH2HDAC1HDAC2HDAC3LTA4H | |
| SCHEMBL20899928 | 0.74 | SLC6A11 (0.42) | KCNH2HDAC1HDAC2ERN1HDAC3 | |
| SCHEMBL19317253 | 0.73 | KCNH2 (0.49) | KCNH2HDAC1HDAC2ERN1HDAC3 | |
| SCHEMBL13742923 | 0.73 | CA2 (0.61) | KCNH2LTA4HCA2CA9CA1 | |
| SCHEMBL27498549 | 0.71 | KCNH2 (0.50) | KCNH2HDAC1HDAC2ERN1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7381728-B2 | Piperazine derivatives useful for the treatment of gastrointestinal disorders | GLAXO GROUP LIMITED (GB) | 2008-06-03 | — | — | US | disclosed |
| US-20070259877-A1 | Piperazine Derivatives Useful for the Treatment of Gastrointestinal Disorders | GLAXO GROUP LIMITED | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259877-A1 | Piperazine Derivatives Useful for the Treatment of Gastrointestinal Disorders | GHSR, GHRHR, GIPR | KCNH2 1314/4885HDAC1 797/4885HDAC2 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.